DDInter1298 DDInter1376
Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Nisoldipine may be used in alone or in combination with other agents in the management of hypertension.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Nisoldipine {u} (Compound) resembles {v} (Compound) Nimodipine
Nisoldipine {u} (Compound) resembles {v} (Compound) Amlodipine
Nisoldipine {u} (Compound) treats {v} (Disease) hypertension
Nisoldipine {u} (Compound) binds {v} (Gene) ABCB1
Nisoldipine {u} (Compound) upregulates {v} (Gene) HMOX1
Nisoldipine {u} (Compound) is included by {v} (Pharmacologic Class) Dihydropyridines
Nisoldipine {u} (Compound) downregulates {v} (Gene) CDC20
Nisoldipine {u} (Compound) causes {v} (Side Effect) Weight decreased
Nisoldipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Nisoldipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Theophylline
Nisoldipine (Compound) resembles Nimodipine (Compound)
Nisoldipine (Compound) resembles Amlodipine (Compound)
Nisoldipine (Compound) treats hypertension (Disease)
Nisoldipine (Compound) binds ABCB1 (Gene)
Nisoldipine (Compound) upregulates HMOX1 (Gene)
Nisoldipine (Compound) is included by Dihydropyridines (Pharmacologic Class)
Nisoldipine (Compound) downregulates CDC20 (Gene)
Nisoldipine (Compound) causes Weight decreased (Side Effect)
Nisoldipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Nisoldipine may cause a minor interaction that can limit clinical effects when taken with Theophylline